Key result
An antigen-binding fragment (Fab) antidote with 20 pM affinity for ticagrelor successfully neutralized the drug, reversed its antiplatelet activity, and normalized bleeding in a mouse surgery model.
Why the study?
Does an antigen-binding fragment (Fab) antidote reverse ticagrelor antiplatelet activity and normalize bleeding in vitro and in vivo?
Does an antigen-binding fragment (Fab) antidote reverse ticagrelor antiplatelet activity and normalize bleeding in vitro and in vivo?
A novel Fab antidote specifically and effectively reverses ticagrelor's antiplatelet effects and normalizes bleeding in preclinical models, showing promise for patients requiring emergency procedures.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for ticagrelor reversal; requires human trials before any practice change.
Buchanan et al. (2015) studied Ticagrelor-induced bleeding. Antigen-binding fragment (Fab) antidote for ticagrelor was evaluated on Neutralization of ticagrelor and reversal of antiplatelet activity and bleeding. An antigen-binding fragment (Fab) antidote with 20 pM affinity for ticagrelor successfully neutralized the drug, reversed its antiplatelet activity, and normalized bleeding in a mouse surgery model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: